시장보고서
상품코드
1485079

신경 바이오마커용 면역 분석 시장 - 세계 산업 규모, 동향, 기회, 예측, 제품별, 질환별, 용도별, 지역별, 경쟁사별(2019-2029년)

Immunoassay for Neurological Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Disease, By Application, By Region and Competition, 2019-2029F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 184 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

신경 바이오마커용 면역 분석 세계 시장은 2023년 6억 2,422만 달러로 평가되었고, 2029년까지 11.45%의 연평균 복합 성장률(CAGR)을 나타내며 예측 기간 동안 꾸준히 성장할 것으로 예상됩니다.

신경계 바이오마커를 위한 면역분석 세계 시장은 다양한 생물학적 샘플에서 신경계 바이오마커를 검출하고 측정하는 데 사용되는 면역분석 기술을 중심으로 한 산업과 관련되어 있습니다. 신경학적 바이오마커는 알츠하이머병, 파킨슨병, 다발성 경화증, 뇌졸중과 같은 신경 질환 및 병태의 존재, 진행 및 심각성에 대한 통찰력을 제공하는 특정 분자 또는 물질을 의미합니다. 이 시장의 성장 동력은 전 세계적으로 신경질환의 유병률 증가와 정확한 조기 진단의 필요성이 대두되고 있다는 점입니다. 면역 분석 기술은 미량의 바이오마커도 높은 민감도와 특이성으로 검출할 수 있기 때문에 임상의는 잠재적인 신경 질환을 조기에 발견하여 보다 효과적인 개입을 할 수 있도록 돕습니다.

시장 개요
예측 기간 2025-2029년
시장 규모 : 2023년 6억 2,422만 달러
시장 규모 : 2029년 11억 9,176만 달러
CAGR : 2024-2029년 11.45%
급성장 부문 시약
최대 시장 북미

효소 결합 면역 흡착 분석법(ELISA), 다중 면역 분석법 등 면역 분석 기술의 발전으로 바이오마커 검출의 정확성과 효율성이 향상되고 있습니다. 또한, 맞춤의료에 대한 관심이 높아지면서 표적치료에 대한 수요가 증가하고 있으며, 정확한 바이오마커 식별은 치료를 조정하는 데 있어 매우 중요한 요소로 작용하고 있습니다. 이 시장은 새로운 신경 바이오마커를 식별하고 면역 측정 플랫폼의 성능을 향상시키기 위한 연구개발의 영향을 받고 있습니다. 면역 측정 프로세스에 자동화와 디지털화를 통합하면 워크플로우의 효율성과 데이터 분석을 강화할 수 있습니다.

신경질환의 복잡성, 특정 질환에 대한 특정 바이오마커의 식별, 결과의 재현성 및 신뢰성 확보 등이 이 시장의 도전과제로 꼽힙니다. 또한, 규제에 대한 고려와 강력한 밸리데이션의 필요성도 시장 역학에 영향을 미칩니다. 결론적으로, 세계 신경 바이오마커용 면역 분석 시장은 신경 질환의 진단과 관리를 개선하는 데 있어 매우 중요한 역할을 하고 있습니다. 면역 분석 기술의 발전과 개인 맞춤형 의료에 대한 관심 증가가 시장 성장의 원동력이 되고 있으며, 바이오마커의 유효성 검증 및 재현성 문제를 해결하는 것이 시장 확대에 필수적이라고 할 수 있습니다.

주요 시장 성장 촉진요인

신경질환의 유병률 증가

고령화 인구 증가

면역 측정 기술의 발전

주요 시장 과제

신경질환의 복잡성

바이오마커의 부족

주요 시장 동향

공동연구 및 파트너십

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 신경 바이오마커용 면역분석 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 제품별(기기, 시약, 서비스)
    • 질환별(알츠하이머병, 파킨슨병, 다발성 경화증, 기타)
    • 용도별(체외진단, 검사)
    • 지역별(북미, 유럽, 아시아태평양, 남미, 중동 및 아프리카)
    • 기업별(2023년)
  • 시장 맵
    • 제품별
    • 질환별
    • 용도별
    • 지역별

제6장 북미의 신경 바이오마커용 면역분석 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 제품별
    • 질환별
    • 용도별
    • 국가별
  • 북미 : 국가별 분석
    • 미국
    • 캐나다
    • 멕시코

제7장 유럽의 신경 바이오마커용 면역분석 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 제품별
    • 질환별
    • 용도별
    • 국가별
  • 유럽 : 국가별 분석
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 스페인

제8장 아시아태평양의 신경 바이오마커용 면역분석 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 제품별
    • 질환별
    • 용도별
    • 국가별
  • 아시아태평양 : 국가별 분석
    • 중국
    • 일본
    • 인도
    • 한국
    • 호주

제9장 남미의 신경 바이오마커용 면역분석 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 제품별
    • 질환별
    • 용도별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제10장 중동 및 아프리카의 신경 바이오마커용 면역분석 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 제품별
    • 질환별
    • 용도별
    • 국가별
  • 중동 및 아프리카 : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트(UAE)

제11장 시장 역학

  • 성장 촉진요인
  • 과제

제12장 시장 동향과 발전

  • 인수합병(M&A)
  • 제품 개발
  • 최근 동향

제13장 Porter's Five Forces 분석

제14장 PESTEL 분석

제15장 경쟁 구도

  • QIAGEN NV
  • Abbott Laboratories Inc.
  • Merck & Co., Inc.
  • Johnson & Johnson Services, Inc.
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Sysmex Corporation
  • F. Hoffmann La-Roche Ltd.
  • Nimble Therapeutics Inc.

제16장 전략적 제안

제17장 리서치사에 대해 & 면책사항

LSH 24.06.04

Global Immunoassay for Neurological Biomarkers Market was valued at USD 624.22 Million in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 11.45% through 2029. The Global Immunoassay for Neurological Biomarkers Market pertains to the industry centered around immunoassay technologies used for detecting and measuring neurological biomarkers in various biological samples. Neurological biomarkers are specific molecules or substances that provide insights into the presence, progression, and severity of neurological disorders and conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and stroke. This market's growth is driven by the increasing prevalence of neurological disorders worldwide and the pressing need for accurate and early diagnosis. Immunoassay techniques offer high sensitivity and specificity in detecting even trace amounts of biomarkers, enabling clinicians to identify potential neurological conditions at an earlier stage, when intervention might be more effective.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 624.22 Million
Market Size 2029USD 1,191.76 Million
CAGR 2024-202911.45%
Fastest Growing SegmentReagents
Largest MarketNorth America

Advancements in immunoassay technologies, including enzyme-linked immunosorbent assays (ELISA) and multiplex immunoassays, have improved the precision and efficiency of biomarker detection. Additionally, the growing interest in personalized medicine has led to a demand for targeted treatments, making accurate biomarker identification crucial for tailoring therapies. The market is influenced by research and development efforts aimed at identifying novel neurological biomarkers and improving the performance of immunoassay platforms. The integration of automation and digitalization in immunoassay processes enhances workflow efficiency and data analysis.

Challenges in this market include the complexity of neurological conditions, the identification of specific biomarkers for certain disorders, and ensuring the reproducibility and reliability of results. Regulatory considerations and the need for robust validation also impact market dynamics. In conclusion, the Global Immunoassay for Neurological Biomarkers Market plays a pivotal role in improving the diagnosis and management of neurological disorders. Advancements in immunoassay technologies and a growing emphasis on personalized medicine are driving its growth, while addressing challenges related to biomarker validation and reproducibility remains essential for further market expansion.

Key Market Drivers

Rising Prevalence of Neurological Disorders

The rising prevalence of neurological disorders is a significant driver in the Global Immunoassay for Neurological Biomarkers Market. Neurological disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and stroke, are becoming increasingly prevalent across the globe. Factors such as aging populations, changing lifestyles, and improved diagnostics contribute to this trend. As the number of individuals affected by these disorders grows, there is a pressing need for accurate and early diagnostic methods to facilitate timely intervention and management. Immunoassay technologies offer a promising solution by enabling the identification and measurement of specific biomarkers associated with neurological conditions. These biomarkers can indicate disease progression, severity, and response to treatment. The immunoassay-based detection of neurological biomarkers allows healthcare professionals to identify potential neurological disorders at earlier stages, enabling the implementation of appropriate therapeutic strategies.

The use of immunoassays supports research efforts to uncover novel biomarkers that could provide insights into disease mechanisms and aid in the development of targeted therapies. The increasing prevalence of neurological disorders underscores the importance of continuous research and development in immunoassay technologies. These advancements not only improve the accuracy and sensitivity of biomarker detection but also contribute to the expansion of the Global Immunoassay for Neurological Biomarkers Market, offering healthcare providers valuable tools to combat the growing burden of neurological diseases.

Growing Aging Population

The growing aging population is a significant driver shaping the Global Immunoassay for Neurological Biomarkers Market. With a substantial increase in the number of elderly individuals globally, the prevalence of age-related neurological disorders is on the rise. This demographic shift has far-reaching implications for healthcare, particularly in the diagnosis, treatment, and management of neurological conditions. As people age, their risk of developing neurological disorders such as Alzheimer's disease, Parkinson's disease, and stroke significantly increases. These conditions can have profound impacts on individuals' quality of life and pose significant challenges for healthcare systems. Immunoassay technologies play a crucial role in addressing these challenges. The accurate and early diagnosis of neurological disorders becomes paramount in an aging population.

Immunoassay-based detection of specific biomarkers associated with these conditions provides a non-invasive and efficient means of identifying early signs and tracking disease progression. This early intervention can lead to improved outcomes and better management strategies for patients. Furthermore, the demand for personalized medicine is amplified in an aging population, where individuals may have unique biomarker profiles and responses to treatment. Immunoassays enable healthcare providers to tailor therapies based on these individual variations, ensuring that interventions are more effective and suitable for each patient. In the Global Immunoassay for Neurological Biomarkers Market, the growing aging population emphasizes the importance of continued research and development efforts to identify novel biomarkers, enhance immunoassay technologies, and improve the precision of neurological disorder diagnoses. By addressing the specific needs of an aging demographic, immunoassay technologies contribute to enhanced patient care, better disease management, and the advancement of neurology as a whole.

Advancements in Immunoassay Technologies

Advancements in immunoassay technologies are playing a pivotal role in shaping the Global Immunoassay for Neurological Biomarkers Market. These technological innovations are revolutionizing the field of diagnostics, especially in the context of neurological disorders. Recent advancements include the development of multiplex immunoassays, which allow the simultaneous detection and measurement of multiple biomarkers in a single sample. This not only saves time but also provides a comprehensive understanding of the patient's condition, aiding in accurate diagnoses and personalized treatment plans. Furthermore, digital immunoassays utilize digital platforms to enhance sensitivity and precision, enabling the quantification of biomarkers at lower concentrations. This is particularly valuable in detecting subtle neurological biomarker changes, especially in the early stages of diseases.

Automated immunoassay systems are streamlining workflows, reducing human error, and improving efficiency in laboratories. These systems offer high-throughput capabilities, making them suitable for processing large volumes of patient samples in a shorter time frame. Integration with data analytics and artificial intelligence (AI) is another notable advancement. AI algorithms can analyze complex biomarker patterns, aiding clinicians in making informed decisions and improving the accuracy of diagnoses. These advancements collectively enhance the reliability, efficiency, and accuracy of immunoassay-based neurological biomarker detection. They empower healthcare professionals to detect neurological disorders earlier, monitor disease progression more effectively, and tailor treatments to individual patients, ultimately improving patient outcomes and advancing the capabilities of neurology diagnostics and research.

Key Market Challenges

Complexity of Neurological Disorders

The complexity of neurological disorders poses a significant challenge in the Global Immunoassay for Neurological Biomarkers Market. Neurological disorders encompass a wide spectrum of conditions, each characterized by intricate and multifaceted pathophysiological mechanisms. This complexity translates into a diverse range of potential biomarkers that can reflect different aspects of disease progression, severity, and response to treatment. The heterogeneity of neurological disorders means that identifying specific biomarkers that accurately represent disease states is a complex task. Researchers need to consider the interplay of various molecular pathways, cellular interactions, and genetic factors that contribute to these disorders. The overlap of symptoms and the lack of unique biomarkers for certain conditions further complicate the biomarker discovery process. The complexity of neurological disorders also presents challenges in the validation and standardization of biomarkers.

Variability in patient populations, disease stages, and underlying genetics can lead to inconsistent biomarker profiles. Ensuring that identified biomarkers are reliable indicators of disease presence or progression across diverse patient groups is a formidable task. Overcoming the complexity of neurological disorders requires comprehensive and interdisciplinary research efforts. Collaborations between neuroscientists, immunologists, geneticists, and clinicians are essential for gaining a deeper understanding of the underlying biology and identifying robust biomarkers. Advanced technologies, such as multi-omics approaches and artificial intelligence, play a crucial role in deciphering the intricate molecular signatures associated with neurological conditions. Ultimately, addressing the complexity of these disorders is vital for developing accurate and effective immunoassay-based diagnostic tools that can aid in early detection and personalized treatment approaches.

Lack of Well-Characterized Biomarkers

The lack of well-characterized biomarkers presents a notable challenge in the Global Immunoassay for Neurological Biomarkers Market. Biomarkers are specific molecules or indicators that provide insights into the presence, progression, and severity of neurological disorders. In many cases, the field of neurology still lacks a comprehensive understanding of which biomarkers reliably represent specific diseases. Neurological disorders are inherently complex, with intricate underlying mechanisms that vary among individuals. This complexity makes it difficult to identify biomarkers that accurately reflect disease states and progression. The absence of well-characterized biomarkers stems from the challenges of defining specific molecules that are consistently associated with particular neurological conditions. The lack of standardized biomarkers hampers the development of reliable immunoassay-based diagnostic tests. Inconsistent or poorly validated biomarkers can lead to inaccurate diagnoses and misinformed treatment decisions. This challenge also affects the comparability of research findings across studies, hindering the progress of biomarker discovery and validation.

Addressing the lack of well-characterized biomarkers requires collaborative efforts between researchers, clinicians, and diagnostic companies. Robust clinical studies involving large and diverse patient populations are crucial for identifying biomarkers with high specificity and sensitivity. Advances in omics technologies and high-throughput profiling methods are aiding in the search for potential biomarkers, although validation and standardization remain key challenges. In conclusion, overcoming the lack of well-characterized biomarkers is essential for advancing the Global Immunoassay for Neurological Biomarkers Market. Rigorous research, comprehensive clinical studies, and interdisciplinary collaborations are necessary to identify and validate biomarkers that accurately reflect the intricate nature of neurological disorders, ultimately enhancing diagnostic accuracy and patient care.

Key Market Trends

Collaborations and Partnerships

Collaborations and partnerships are playing a crucial role in shaping the Global Immunoassay for Neurological Biomarkers Market. In this context, collaborations refer to the cooperation between diverse stakeholders, including research institutions, diagnostic companies, pharmaceutical manufacturers, and healthcare providers. These collaborations facilitate the sharing of knowledge, expertise, and resources, ultimately accelerating progress in biomarker research and the development of immunoassay-based diagnostic solutions. Partnerships and collaborations offer several benefits in the field of neurological biomarkers. They leverage the collective strengths of different organizations, enabling access to specialized skills, advanced technologies, and extensive patient data. Academic research institutions contribute to the discovery and validation of novel biomarkers, while diagnostic companies bring expertise in assay development and commercialization.

Pharmaceutical manufacturers play a role in translating biomarker research into actionable insights for drug development and treatment strategies. Healthcare providers contribute clinical expertise and real-world patient data, ensuring that developed diagnostic tools are clinically relevant and effective in practice. Collaborations also address the complexity of neurological disorders, which require multidisciplinary approaches. Neuroscientists, immunologists, geneticists, clinicians, and engineers working together can provide comprehensive insights into disease mechanisms and biomarker profiles. In the context of the Global Immunoassay for Neurological Biomarkers Market, collaborations and partnerships expedite the translation of research findings into practical diagnostic solutions. By fostering an environment of open communication and shared goals, these collaborative efforts enhance diagnostic accuracy, contribute to personalized treatment approaches, and ultimately benefit patients by improving neurological disorder management.

Segmental Insights

Product Insights

Based on product, reagents emerged as the fastest growing segment in the Global Immunoassay for Neurological Biomarkers Market during the forecast period. Continual progress in neuroscience research has uncovered new biomarkers linked to diverse neurological conditions. Immunoassays offer a dependable and precise means of measuring these biomarkers in biological specimens. The evolution of high-throughput immunoassay platforms, boasting enhanced sensitivity, specificity, and multiplexing capabilities, has broadened the scope of immunoassay applications in neurological biomarker investigations. Initiatives such as awareness campaigns and screening programs targeting the early detection of neurological disorders are bolstering the demand for immunoassays within this market segment.

Disease Insights

Based on disease, Alzheimer's Disease emerged as the dominating segment in the Global Immunoassay for Neurological Biomarkers Market during the forecast period. Alzheimer's disease stands out as the most prevalent type of dementia worldwide, constituting a significant proportion of neurological disorders. This prevalence underscores the imperative for developing and employing biomarkers to detect and track the disease's progression at its early stages. There is considerable research directed towards comprehending the pathophysiology of Alzheimer's and pinpointing new biomarkers capable of signaling the disease's trajectory. Immunoassays emerge as pivotal tools offering precise and sensitive means of measuring these biomarkers, thus asserting their prominence in the market. In regions with robust healthcare infrastructures and established diagnostic facilities, there's a tendency to adopt cutting-edge diagnostic technologies like immunoassays for the detection and monitoring of Alzheimer's disease.

Regional Insights

Based on region, North America dominated the Global Immunoassay for Neurological Biomarkers Market in 2023. This dominance can be attributed to the rising incidence of chronic diseases, encompassing breast cancer, cardiology, and neurological disorders, within the region. The demand for immunoassays is particularly driven by the need for accurate diagnosis and monitoring of neurological conditions, given their significant impact on public health and healthcare expenditure. North America's advanced healthcare infrastructure, coupled with substantial investments in research and development, further propels the adoption of immunoassays for neurological biomarkers. As the prevalence of neurological disorders continues to rise globally, North America remains at the forefront of innovation and market growth in the immunoassay sector, shaping the landscape of neurological diagnostics and therapeutics.

Key Market Players

QIAGEN NV

Abbott Laboratories Inc.

Merck & Co., Inc.

Johnson & Johnson Services, Inc.

Thermo Fisher Scientific, Inc.

Bio-Rad Laboratories, Inc.

Sysmex Corporation

F. Hoffmann La-Roche Ltd.

Nimble Therapeutics Inc.

Report Scope:

In this report, the Global Immunoassay for Neurological Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Immunoassay for Neurological Biomarkers Market, By Product:

    Instruments Reagents Services

Immunoassay for Neurological Biomarkers Market, By Disease:

    Alzheimer's Disease Parkinson's Disease Multiple Sclerosis Others

Immunoassay for Neurological Biomarkers Market, By Application:

    In Vitro Diagnostics Research

Immunoassay for Neurological Biomarkers Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Immunoassay for Neurological Biomarkers Market.

Available Customizations:

Global Immunoassay for Neurological Biomarkers Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Immunoassay for Neurological Biomarkers Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Instruments, Reagents, Services)
    • 5.2.2. By Disease (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Others)
    • 5.2.3. By Application (In Vitro Diagnostics, Research)
    • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 5.2.5. By Company (2023)
  • 5.3. Market Map
    • 5.3.1. By Product
    • 5.3.2. By Disease
    • 5.3.3. By Application
    • 5.3.4. By Region

6. North America Immunoassay for Neurological Biomarkers Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Disease
    • 6.2.3. By Application
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Immunoassay for Neurological Biomarkers Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Disease
        • 6.3.1.2.3. By Application
    • 6.3.2. Canada Immunoassay for Neurological Biomarkers Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Disease
        • 6.3.2.2.3. By Application
    • 6.3.3. Mexico Immunoassay for Neurological Biomarkers Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Disease
        • 6.3.3.2.3. By Application

7. Europe Immunoassay for Neurological Biomarkers Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Disease
    • 7.2.3. By Application
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Immunoassay for Neurological Biomarkers Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Disease
        • 7.3.1.2.3. By Application
    • 7.3.2. France Immunoassay for Neurological Biomarkers Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Disease
        • 7.3.2.2.3. By Application
    • 7.3.3. United Kingdom Immunoassay for Neurological Biomarkers Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Disease
        • 7.3.3.2.3. By Application
    • 7.3.4. Italy Immunoassay for Neurological Biomarkers Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Disease
        • 7.3.4.2.3. By Application
    • 7.3.5. Spain Immunoassay for Neurological Biomarkers Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Disease
        • 7.3.5.2.3. By Application

8. Asia Pacific Immunoassay for Neurological Biomarkers Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Disease
    • 8.2.3. By Application
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Immunoassay for Neurological Biomarkers Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Disease
        • 8.3.1.2.3. By Application
    • 8.3.2. Japan Immunoassay for Neurological Biomarkers Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Disease
        • 8.3.2.2.3. By Application
    • 8.3.3. India Immunoassay for Neurological Biomarkers Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Disease
        • 8.3.3.2.3. By Application
    • 8.3.4. South Korea Immunoassay for Neurological Biomarkers Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Disease
        • 8.3.4.2.3. By Application
    • 8.3.5. Australia Immunoassay for Neurological Biomarkers Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Disease
        • 8.3.5.2.3. By Application

9. South America Immunoassay for Neurological Biomarkers Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Disease
    • 9.2.3. By Application
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Immunoassay for Neurological Biomarkers Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Disease
        • 9.3.1.2.3. By Application
    • 9.3.2. Argentina Immunoassay for Neurological Biomarkers Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Disease
        • 9.3.2.2.3. By Application
    • 9.3.3. Colombia Immunoassay for Neurological Biomarkers Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Disease
        • 9.3.3.2.3. By Application

10. Middle East and Africa Immunoassay for Neurological Biomarkers Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Disease
    • 10.2.3. By Application
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Immunoassay for Neurological Biomarkers Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Disease
        • 10.3.1.2.3. By Application
    • 10.3.2. Saudi Arabia Immunoassay for Neurological Biomarkers Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Disease
        • 10.3.2.2.3. By Application
    • 10.3.3. UAE Immunoassay for Neurological Biomarkers Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Disease
        • 10.3.3.2.3. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition
  • 12.2. Product Development
  • 12.3. Recent Developments

13. Porter's analysis

14. PESTEL analysis

15. Competitive Landscape

  • 15.1. QIAGEN NV
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
  • 15.2. Abbott Laboratories Inc.
  • 15.3. Merck & Co., Inc.
  • 15.4. Johnson & Johnson Services, Inc.
  • 15.5. Thermo Fisher Scientific, Inc.
  • 15.6. Bio-Rad Laboratories, Inc.
  • 15.7. Sysmex Corporation
  • 15.8. F. Hoffmann La-Roche Ltd.
  • 15.9. Nimble Therapeutics Inc.

16. Strategic Recommendations

17. About Us & Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제